Aldeyra Therapeutics Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aldeyra Therapeutics stock.
View analyst ratings for Aldeyra Therapeutics or view top-rated stocks.

Wall Street analysts have given Aldeyra Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aldeyra Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aldeyra Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 6,070,000 shares, an increase of 42.2% from the June 15th total of 4,270,000 shares. Based on an average daily trading volume, of 2,380,000 shares, the short-interest ratio is currently 2.6 days. Currently, 10.8% of the shares of the stock are short sold.
View Aldeyra Therapeutics' Short Interest.

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Aldeyra Therapeutics.

Aldeyra Therapeutics will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) posted its earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.29) by $0.04.
View Aldeyra Therapeutics' earnings history.

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALDX stock has increased by 219.0% and is now trading at $8.90.
View which stocks have been most impacted by COVID-19.

9 equities research analysts have issued twelve-month price targets for Aldeyra Therapeutics' shares. Their forecasts range from $15.00 to $32.00. On average, they expect Aldeyra Therapeutics' share price to reach $25.63 in the next year. This suggests a possible upside of 187.9% from the stock's current price.
View analysts' price targets for Aldeyra Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aldeyra Therapeutics include Organogenesis (ORGO), Ligand Pharmaceuticals (LGND), Myovant Sciences (MYOV), Nuvation Bio (NUVB), Centessa Pharmaceuticals (CNTA), MorphoSys (MOR), Axsome Therapeutics (AXSM), Xencor (XNCR), Deciphera Pharmaceuticals (DCPH), Aurinia Pharmaceuticals (AUPH), Global Blood Therapeutics (GBT), Indivior (INVVY), Amarin (AMRN), Constellation Pharmaceuticals (CNST) and NGM Biopharmaceuticals (NGM).
View all of ALDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Aldeyra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.03%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Joshua Reed, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends for Aldeyra Therapeutics.

ALDX stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Perceptive Advisors Llc, Richard Douglas, and Todd C Brady.
View insider buying and selling activity for Aldeyra Therapeutics or or view top insider-buying stocks.

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALDX stock can currently be purchased for approximately $8.90.

Aldeyra Therapeutics has a market capitalization of $512.91 million. The biotechnology company earns $-37,550,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

Aldeyra Therapeutics employs 15 workers across the globe.

The official website for Aldeyra Therapeutics is www.ampliphibio.com.

Aldeyra Therapeutics is headquartered at 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421.

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]